Publications by authors named "Sandra Horning"

Claim this Profile
I
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902.
Francine M Foss, Xin Victoria Wang, Selina M Luger, Opeyemi Jegede, Kenneth B Miller, Sandra J Horning

Transfusion· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
Amy K Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Sandra J Horning

J Immunother Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Tara O Henderson, Susan K Parsons, Kristen E Wroblewski, Lu Chen, Fangxin Hong, Sandra Horning

Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new cancer ecosystem.
Sandra J Horning

Science· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).
Stefan K Barta, Hailun Li, Howard S Hochster, Fangxin Hong, Edie Weller, Sandra J Horning

Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
Michael E Williams, Fangxin Hong, Randy D Gascoyne, Lynne I Wagner, John C Krauss, Sandra J Horning

Br J Haematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma.
Vaishalee P Kenkre, Fangxin Hong, James R Cerhan, Marcia Lewis, Leslie Sullivan, Sandra J Horning

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.
Catherine S Diefenbach, Hailun Li, Fangxin Hong, Leo I Gordon, Richard I Fisher, Sandra J Horning

Br J Haematol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
Thomas E Witzig, Fangxin Hong, Ivana N Micallef, Randy D Gascoyne, Ahmet Dogan, Sandra J Horning

Br J Haematol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
Lode J Swinnen, Hailun Li, Andrew Quon, Randy Gascoyne, Fangxin Hong, Sandra J Horning

Br J Haematol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Ranjana H Advani, Fangxin Hong, Richard I Fisher, Nancy L Bartlett, K Sue Robinson, Sandra J Horning

J Clin Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).
Lynne I Wagner, Fengmin Zhao, Fangxin Hong, Michael E Williams, Randy D Gascoyne, Sandra J Horning

J Clin Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.
Brad S Kahl, Fangxin Hong, Michael E Williams, Randy D Gascoyne, Lynne I Wagner, Sandra J Horning

J Clin Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient priority in the era of patent expiries.
Sandra Horning

Lancet Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
Kristen Ganjoo, Fangxin Hong, Sandra J Horning, Randy D Gascoyne, Yasodha Natkunam

Leuk Lymphoma· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
Julie E Chang, Hailun Li, Mitchell R Smith, Randy D Gascoyne, Elisabeth M Paietta, Sandra J Horning

Blood· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
Ranjana H Advani, Sandra J Horning, Richard T Hoppe, Sarah Daadi, John Allen

J Clin Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.
Sally Arai, Michelle Fanale, Sven DeVos, Andreas Engert, Tim Illidge, Sandra J Horning

Leuk Lymphoma· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing standards for breakthrough therapy designation in oncology.
Sandra J Horning, Daniel A Haber, Wendy K D Selig, S Percy Ivy, Samantha A Roberts

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.
Daryl Tan, Sandra J Horning, Richard T Hoppe, Ronald Levy, Saul A Rosenberg

Blood· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).
Daniel R Greenwald, Hailun Li, Selina M Luger, Ronald S Go, David King, Sandra Horning

J Hematol Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.
Jennifer A Kanakry, Hailun Li, Lan L Gellert, M Victor Lemas, Wen-son Hsieh, Sandra J Horning

Blood· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
Andrew M Evens, Fangxin Hong, Leo I Gordon, Richard I Fisher, Nancy L Bartlett, Sandra J Horning

Br J Haematol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
Leo I Gordon, Fangxin Hong, Richard I Fisher, Nancy L Bartlett, Joseph M Connors, Sandra J Horning

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Michael Zach Koontz, Sandra J Horning, Raymond Balise, Peter L Greenberg, Saul A Rosenberg

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis